NYSE:GLS

Gelesis (GLS) Stock Price, News & Analysis

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)

Free GLS Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.11
▼
$0.33
52-Week Range: N/A

Volume: 185,100 shs
Average Volume: 386,034 shs
Market Capitalization: $11.63 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Gelesis alerts:

Ad InvestorPlace

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

>>Check out what this A.I. Perfect Storm is<<

About Gelesis Stock (NYSE:GLS)

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Ad InvestorPlace

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

>>Check out what this A.I. Perfect Storm is<<

GLS Stock News Headlines

December 9, 2023 | morningstar.com

Gelesis Holdings Inc GLSHQ

April 11, 2023 | msn.com

NYSE to suspend trading immediately in Gelesis Holdings

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

April 10, 2023 | finance.yahoo.com

NYSE to Suspend Trading Immediately in Gelesis Holdings, Inc. (GLS) and Commence Delisting Proceedings

March 29, 2023 | msn.com

Looking Into Gelesis Holdings's Return On Capital Employed

March 28, 2023 | finance.yahoo.com

Gelesis Reports Fourth Quarter and Full Year 2022 Results

January 27, 2023 | seekingalpha.com

GLS Gelesis Holdings, Inc.

January 5, 2023 | finance.yahoo.com

Gelesis to Participate in the 25th Annual ICR Conference

April 16, 2024 | InvestorPlace (Ad)

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

January 4, 2023 | technews.tmcnet.com

NYSE to Suspend Trading Immediately in Warrants of Gelesis Holdings, Inc. (GLS WS) and Commence Delisting Proceedings

November 21, 2022 | finance.yahoo.com

Gelesis Reports Upcoming Participation in Wolfe Research’s Annual Consumer Growth Conference

November 18, 2022 | finance.yahoo.com

Gelesis Receives Notice of NYSE Market Capitalization Listing Rule Non-Compliance

November 14, 2022 | seekingalpha.com

Gelesis Holdings, Inc. (GLS) Q3 2022 Earnings Call Transcript

November 14, 2022 | finance.yahoo.com

Gelesis Reports Third Quarter 2022 Results

November 7, 2022 | finance.yahoo.com

Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022

November 4, 2022 | finance.yahoo.com

Gelesis Receives Notice of NYSE Trading Share Price Listing Rule Non-Compliance

November 2, 2022 | finance.yahoo.com

Data Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical Models Compared to Prebiotics

November 1, 2022 | finance.yahoo.com

Dr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis’ Oral Hydrogel Treatment GS200 at Obesity Week

October 5, 2022 | ca.finance.yahoo.com

Investors in Gelesis Holdings (NYSE:GLS) have unfortunately lost 89% over the last year

September 9, 2022 | morningstar.com

Gelesis Holdings Inc GLS Stock Analysis

September 8, 2022 | finance.yahoo.com

Gelesis to Participate in the Jefferies Virtual Fitness & Wellness Summit

August 25, 2022 | finance.yahoo.com

Clinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New Gelesis Oral Hydrogel May Improve Insulin Sensitivity and Favorably Impact Metabolic Syndrome

August 24, 2022 | nasdaq.com

Investors one-year losses grow to 89% as the stock sheds US$21m this past week

August 17, 2022 | finance.yahoo.com

REPLAY: Fight Obesity With Biotech – Gelesis CEO, CFO in Fireside Chat

August 17, 2022 | msn.com

Analyzing Gelesis Holdings Short Interest

August 17, 2022 | finance.yahoo.com

Gelesis to Participate in Fireside Chat with IPO Edge Today at 2:00 PM ET

August 16, 2022 | finance.yahoo.com

Arming Consumers to Fight Obesity with Biotech – Join CEO and CFO of Gelesis in Fireside Chat Wednesday at 2 ET

See More Headlines

Receive GLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gelesis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/15/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:GLS
CUSIP: N/A
CIK: 1805087
Web: www.gelesis.com
Phone: N/A
Fax: N/A
Employees: 2
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.40)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-56,030,000.00
Net Margins: -221.38%
Pretax Margin: -214.62%
Return on Equity: N/A
Return on Assets: -14.98%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.30
Quick Ratio: 0.21

Sales & Book Value

Annual Sales: $25.77 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.34) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 73,333,000
Free Float: 64,606,000
Market Cap: $11.63 million
Optionable: Not Optionable
Beta: 0.88

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Yishai Zohar (Age 59)
Founder, Pres, CEO & Director
Comp: $689.95k
Mr. Elliot Maltz CPA (Age 37)
CFO & Treasurer
Comp: $486.26k
Dr. David Pass Pharm.D. (Age 53)
COO & Chief Commercial Officer
Dr. Elaine Chiquette Pharm.D. (Age 55)
Chief Scientific Officer
Ms. Joy Bauer M.S.
MS, RDN, Chief Nutrition Officer of Plenity

Key Competitors

View All Competitors

This page (NYSE:GLS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Gelesis (GLS) Stock Price, News & Analysis

About Gelesis Stock (NYSE:GLS)

GLS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info